Prognostic value of early response assessment using (18F)FDG-PET in patients with advanced non-small cell lung cancer treated with tyrosine-kinase inhibitors

2017 ◽  
Vol 65 (5) ◽  
pp. 935-941 ◽  
Author(s):  
Jun Ma ◽  
Xiaojing Wu ◽  
Jianghong Li ◽  
Zhihua Wang ◽  
Yi Wang
Keyword(s):  
Lung Cancer ◽  
Fdg Pet ◽  
Prognostic Value ◽  
Kinase Inhibitors ◽  
Response Assessment ◽  
Early Response ◽  
Small Cell ◽  
Small Cell Lung ◽  
Positron Emission ◽  
Early Response Assessment

The purpose of this meta-analysis was to determine the prognostic value of early response assessment using (18F)fluorodeoxyglucose (FDG)-positron emission thermography (PET) in patients with advanced non-small cell lung cancer (NSCLC) treated with tyrosine-kinase inhibitors (TKIs). MEDLINE, PubMed, Cochrane, EMBASE, and Google Scholar databases were searched until August 1, 2016 using the keywords non-small cell lung carcinoma, positron-emission tomography, fluorodeoxyglucose, prognosis, disease progression, survival, erlotinib, gefitinib, and afatinib. Inclusion criteria were studies of patients with stage III or IV NSCLC treated with a TKI and had response assessed by FDG-PET. Outcome measures were overall survival (OS) and progression-free survival (PFS). Of the 167 articles identified, 10 studies including 302 patients were included in the analysis. In 8 studies, patients were treated with erlotinib, and in 2 they were treated with gefitinib. The overall analysis revealed that early metabolic response was statistically associated with improved OS (HR=0.54; 95% CI 0.46 to 0.63; p<0.001), and with longer PFS (HR=0.23; 95% CI 0.17 to 0.33; p<0.001). Early response of patients with NSCLC treated with TKIs identified on FDG-PET is associated with improved OS and PFS.

Prognostic value of early response assessment using 18F-FDG PET/CT in chemotherapy-treated patients with non-small-cell lung cancer

2015 ◽  
Vol 36 (12) ◽  
pp. 1187-1194 ◽  
Author(s):  
Eun Ji Han ◽  
Young Jun Yang ◽  
Ji Chan Park ◽  
Suk Young Park ◽  
Woo Hee Choi ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Prognostic Value ◽  
Response Assessment ◽  
Early Response ◽  
Small Cell ◽  
Small Cell Lung ◽  
Pet Ct ◽  
18F Fdg ◽  
Early Response Assessment ◽  
Fdg Pet Ct

scholarly journals Predictive value of integrated18F-FDG PET/MRI in the early response to nivolumab in patients with previously treated non-small cell lung cancer

2020 ◽  
Vol 8 (1) ◽  
pp. e000349 ◽  
Author(s):  
Yukihiro Umeda ◽  
Miwa Morikawa ◽  
Masaki Anzai ◽  
Shingo Ameshima ◽  
Maiko Kadowaki ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Overall Survival ◽  
Small Cell Lung Cancer ◽  
Fdg Pet ◽  
Progression Free Survival ◽  
Early Response ◽  
Small Cell ◽  
Small Cell Lung ◽  
Free Survival ◽  
Previously Treated

BackgroundThe early response to treatment with immune-checkpoint inhibitors is difficult to evaluate. We determined whether changes in integrated [18F]-fluoro-2-deoxy-D-glucose positron emission tomography/MRI (18F-FDG PET/MRI) parameters after the first 2 weeks of antiprogrammed death-1 antibody nivolumab therapy could predict the response of patients with non-small cell lung cancer (NSCLC).MethodsTwenty-five patients with previously treated NSCLC were enrolled prospectively and underwent18F-FDG PET/MRI before and at 2 weeks after nivolumab therapy. Changes in maximal standardized uptake value, total lesion glycolysis (ΔTLG) and apparent diffusion coefficient (ΔADC) between the two scans were calculated and evaluated for their associations with the clinical response to therapy.ResultsThe disease control rate was 64%. Patients with non-progressive disease (non-PD) had significantly decreased TLG, increased ADCmean(ie, negative ΔADCmean) and lower ΔTLG+ΔADCmeanthan patients with PD. Among the parameters tested, receiver operating characteristic curve analysis revealed that a cut-off value of 16.5 for ΔTLG+ΔADCmeanhad the highest accuracy (92%) for distinguishing between patients with non-PD and PD. A ΔTLG+ΔADCmeanvalue <16.5 was significantly associated with longer median progression-free survival (9.0 vs 1.8 months, p<0.00001) and overall survival (23.6 vs 4.7 months, p=0.0001) compared with ΔTLG+ΔADCmeanvalue ≥16.5. A multivariate Cox model revealed that ≥16.5 ΔTLG+ΔADCmeanwas an independent predictor of shorter progression-free survival (HR 37.7) and overall survival (HR 9.29).ConclusionsA combination of ΔTLG and ΔADCmeanmeasured by integrated18F-FDG PET/MRI may have value as a predictor of the response and survival of patients with NSCLC following nivolumab therapy.Trial registration numberUMIN 000020707.

Sign in / Sign up

Export Citation Format

Share Document